Related references
Note: Only part of the references are listed.TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer
Channing Paller et al.
PROSTATE (2019)
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells
Elia Farah et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Nithya Krishnamurthy et al.
CANCER TREATMENT REVIEWS (2018)
Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway
Xueran Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance
Ranran Li et al.
FRONTIERS IN PHARMACOLOGY (2018)
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Marcello Tucci et al.
ONCOTARGETS AND THERAPY (2018)
A novel non-canonical Wnt signature for prostate cancer aggressiveness
Elise Sandsmark et al.
ONCOTARGET (2017)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Epithelial-mesenchymal transition in prostate cancer: an overview
Micaela Montanari et al.
ONCOTARGET (2017)
Microcystin-LR promotes cell proliferation in the mice liver by activating Akt and p38/ERK/JNK cascades
Jinghui Liu et al.
CHEMOSPHERE (2016)
SOX9 drives WNT pathway activation in prostate cancer
Fen Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Jamie N. Anastas et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2012)
Wnt signal transduction pathways
Yuko Komiya et al.
Organogenesis (2010)
Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors
Michael D. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Share Paper
